Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OmpA recombinant protein vaccine
- Development stage
- Preclinical
- Lead developer
- Qom University of Medical Sciences
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intranasal, Subcutaneous
01
Overview
OmpA recombinant protein vaccine is a subunit vaccine platform utilizing recombinant outer membrane protein A (OmpA) as an immunogen to prevent infections caused by Gram-negative bacteria, most notably multidrug-resistant (MDR) *Acinetobacter baumannii*. OmpA is a highly conserved, abundant outer membrane porin that plays a critical role in bacterial adhesion, invasion, biofilm formation, and antibiotic resistance. Immunization with recombinant OmpA stimulates the host immune system to produce high titers of antigen-specific antibodies (such as IgG1, IgG2a, and IgG2b) and modulates cytokine responses, thereby providing protective immunity and reducing bacterial burden in key organs like the lungs, spleen, and liver upon pathogen challenge.
- Other names
- OmpA subunit vaccinerecombinant OmpA vaccinerOmpA vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)OmpA (Outer membrane protein A)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on OmpA recombinant protein vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OmpA recombinant protein vaccine.